Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

Inclusion Criteria: * Histologically confirmed glioblastoma * Newly diagnosed disease * Scheduled to receive standard post-surgical (i.e., biopsy or resection) temozolomide and radiotherapy * Must have residual, contrast-enhancing tumor (≥ 1 centimeter in ≥ 1 dimension) * Patients must be maintained on a stable corticosteroid regimen for 5 days prior to their baseline scan and for 5 days prior to their first vascular MRI; the dose of steroids should remain the same during the baseline vascular MRIs * Archival tumor tissue available for molecular analysis * No intratumoral hemorrhage or peritumoral hemorrhage by MRI * Karnofsky performance status 60-100% * Leukocytes ≥ 3,000/mcl * Absolute neutrophil count ≥ 1,500/mcL * Platelet count ≥ 100,000/mcL * Hemoglobin ≥ 8 g/dL * Total bilirubin normal * AST/ALT ≤ 2.5 times upper limit of normal * Creatinine normal OR creatinine clearance ≥ 60 mL/min * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Proteinuria ≤ 1+ on two consecutive dipsticks ≥ 7 days apart * Mini-mental status examination score ≥ 15 * Must be able to tolerate MRI and must consent to participate in additional Vascular Imaging Procedures per protocol * CT scans cannot be substituted for MRI * Mean QTc ≤ 500 msec (with Bazett's correction) by electrocardiogram * No concurrent malignancy except curatively treated basal cell or squamous cell carcinoma skin cancer or carcinoma in situ of the cervix or breast …